Key result
Pulsed field ablation did not demonstrate superior efficacy over radiofrequency ablation for paroxysmal AF (77% vs 77% success; P=0.84), but had fewer procedure-related serious adverse events.
Why the study?
Does pulsed field ablation improve single-procedure success compared to radiofrequency ablation in patients with symptomatic, drug-resistant paroxysmal atrial fibrillation?
RCT (n=292)
Open-label
1:1
Yes
Does pulsed field ablation improve single-procedure success compared to radiofrequency ablation in patients with symptomatic, drug-resistant paroxysmal atrial fibrillation?
Absolute Event Rate: 77% vs 77%
p-value: p=.84
Authors
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This important study sets the bar for ongoing prospective trials and argues strongly for changes in practice and changes in guidelines. Given that the mean ejection fraction in this study was 60%, it argues that at least for patients with a normal ejection fraction, spending an extra 5 min placing a conduction system lead in the interventricular septum is worth the time and effort, with better clinical outcomes.”
“BEAT PAROX-AF is a landmark in comparative ablation, demonstrating that PFA matches optimized RFA in efficacy while offering shorter procedures and a reassuring safety profile. The absence of superiority underscores that procedural innovation alone cannot overcome the biological drivers of AF, constrained by comorbidities and atrial remodelling. The way forward lies in synergy: advanced ablation technologies combined with structured risk factor modification.”
“Implanters need to keep in mind that although follow-up in this study was for 4 years, the average pulse generator longevity is upwards of 10 years and it is likely that the mortality and heart failure curves would continue to separate. It is also important to recognize that this was an on-treatment analysis, and we should await the results of large, randomized clinical trials for a definitive answer.”
In patients with paroxysmal AF, pulsed field ablation did not demonstrate superior efficacy compared to radiofrequency ablation for single-procedure success at 12 months, but was associated with fewer safety events.
F Crea (2026) conducted an RCT in Symptomatic, drug-resistant paroxysmal atrial fibrillation (n=292). Pulsed field ablation (PFA) vs. Radiofrequency ablation (RFA) was evaluated on Single-procedure success rate after 12 months defined as the absence of recurrence 30 s atrial arrhythmia, cardioversion, class I/III antiarrhythmic drug resumption, or any repeat ablation (p=.84). Pulsed field ablation did not demonstrate superior efficacy over radiofrequency ablation for paroxysmal AF (77% vs 77% success; P=0.84), but had fewer procedure-related serious adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: